News

Luye Pharma’s Licensed Drug Lurbinectedin Included in NCCN Guidelines in the U.S.

Luye Pharma Group’s partner PharmaMar announced that its innovative anticancer drug, Lurbinectedin, has been added to the National Comprehensive Cancer Network’s (NCCN®) Clinical Practice Guidelines in Oncology for the treatment of Small Cell Lung Cancer (SCLC).
July 15,2020

Clinical Trials for Luye Pharma’s Licensed Drug Lurbinectedin to Begin in China Soon

Luye Pharma Group has announced that the clinical trials application for Lurbinectedin, an innovative anticancer drug licensed-in from PharmaMar, has been accepted by the Center for Drug Evaluation of China, for the treatment of Small Cell Lung Cancer.
June 29,2020
23
2020-06
Luye Pharma to Start Clinical Trials for Its Next-Generation NTRK Inhibitor in China, The drug is expected to improve the treatment of patients with drug resistance to NTRK gene fusion
19
2020-06
Luye Pharma's Innovative Formulation LY03013 Soon to Begin Clinical Trials in China, Helping Alzheimer’s patients achieve more stable outcomes
16
2020-06
Lurbinectedin Receives U.S. FDA Accelerated Approval for Treating Metastatic SCLC——Luye Pharma Working with PharmaMar to Develop the Drug in China
12
2020-06
The First Combinational Liposome Formulation in China Soon to Begin Clinical Trials, Medication Designed to Improve Efficacy of First-line Treatment for Patients with Advanced ...
11
2020-06
TGA Grants "Provisional Approval Pathway" for Lurbinectedin in Treatment for Relapsed Small Cell Lung Cancer in Australia -- Luye Pharma Working with PharmaMar to Develop the Drug in ...
09
2020-06
Luye Pharma's Rivastigmine Transdermal Patch Receives Market Approval in China
01
2020-06
Luye Pharma Enters Distribution and Marketing Partnerships in South Korea, Hong Kong, and Thailand for Seroquel® and Seroquel XR®
21
2020-05
Marketing Authorization Application for Luye Pharma's Rivastigmine Multi-Day Transdermal Patch Product Rivalif® under Review at EU Competent Authorities
13
2020-05
Luye Pharma Grants Exclusive Promotion Rights to Moksha8, Deepening Strategic Presence in Latin America for CNS Business
08
2020-05
Luye Pharma Submits IND Application for Denosumab Injection in the U.S.
1
2
3
4
5
News
Luye Pharma’s Licensed Drug Lurbinectedin Included in NCCN Guidelines in the U.S.
Luye Pharma Group’s partner PharmaMar announced that its innovative anticancer drug, Lurbinectedin, has been added to the National Comprehensive Cancer Network’s (NCCN®) Clinical Practice Guidelines in Oncology for the treatment of Small Cell Lung Cancer (SCLC).

July 15,2020
Clinical Trials for Luye Pharma’s Licensed Drug Lurbinectedin to Begin in China Soon
Luye Pharma Group has announced that the clinical trials application for Lurbinectedin, an innovative anticancer drug licensed-in from PharmaMar, has been accepted by the Center for Drug Evaluation of China, for the treatment of Small Cell Lung Cancer.

June 29,2020
06-23
2020
Luye Pharma to Start Clinical Trials for Its Next-Generation NTRK Inhibitor in China, The drug is expected to improve the treatment of patients with drug resistance to NTRK gene fusion
06-19
2020
Luye Pharma's Innovative Formulation LY03013 Soon to Begin Clinical Trials in China, Helping Alzheimer’s patients achieve more stable outcomes
06-16
2020
Lurbinectedin Receives U.S. FDA Accelerated Approval for Treating Metastatic SCLC——Luye Pharma Working with PharmaMar to Develop the Drug in China
06-12
2020
The First Combinational Liposome Formulation in China Soon to Begin Clinical Trials, Medication Designed to Improve Efficacy of First-line Treatment for Patients with Advanced Colorectal Cancer
06-11
2020
TGA Grants "Provisional Approval Pathway" for Lurbinectedin in Treatment for Relapsed Small Cell Lung Cancer in Australia -- Luye Pharma Working with PharmaMar to Develop the Drug in China
06-09
2020
Luye Pharma's Rivastigmine Transdermal Patch Receives Market Approval in China
06-01
2020
Luye Pharma Enters Distribution and Marketing Partnerships in South Korea, Hong Kong, and Thailand for Seroquel® and Seroquel XR®
05-21
2020
Marketing Authorization Application for Luye Pharma's Rivastigmine Multi-Day Transdermal Patch Product Rivalif® under Review at EU Competent Authorities
05-13
2020
Luye Pharma Grants Exclusive Promotion Rights to Moksha8, Deepening Strategic Presence in Latin America for CNS Business
05-08
2020
Luye Pharma Submits IND Application for Denosumab Injection in the U.S.
1
2
3
4
5